Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Abstract Objective Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karin Holm, Maria N. Lundgren, Jens Kjeldsen-Kragh, Oskar Ljungquist, Blenda Böttiger, Christian Wikén, Jonas Öberg, Nils Fernström, Ebba Rosendal, Anna K. Överby, Julia Wigren Byström, Mattias Forsell, Mona Landin-Olsson, Magnus Rasmussen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	SARS-CoV2 COVID-19 Convalescent plasma Oxygen therapy Desaturation Medicine R Biology (General) QH301-705.5 Science (General) Q1-390
Acceso en línea:	https://doaj.org/article/b7713b8a6ec64937b394d31d9f097f2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7713b8a6ec64937b394d31d9f097f2f
record_format	dspace
spelling	oai:doaj.org-article:b7713b8a6ec64937b394d31d9f097f2f2021-12-05T12:18:39ZConvalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden10.1186/s13104-021-05847-71756-0500https://doaj.org/article/b7713b8a6ec64937b394d31d9f097f2f2021-12-01T00:00:00Zhttps://doi.org/10.1186/s13104-021-05847-7https://doaj.org/toc/1756-0500Abstract Objective Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19. Results Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6–15) for the convalescent plasma group and 7 days (IQR 5–9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08–2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.Karin HolmMaria N. LundgrenJens Kjeldsen-KraghOskar LjungquistBlenda BöttigerChristian WikénJonas ÖbergNils FernströmEbba RosendalAnna K. ÖverbyJulia Wigren ByströmMattias ForsellMona Landin-OlssonMagnus RasmussenBMCarticleSARS-CoV2COVID-19Convalescent plasmaOxygen therapyDesaturationMedicineRBiology (General)QH301-705.5Science (General)Q1-390ENBMC Research Notes, Vol 14, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV2 COVID-19 Convalescent plasma Oxygen therapy Desaturation Medicine R Biology (General) QH301-705.5 Science (General) Q1-390
spellingShingle	SARS-CoV2 COVID-19 Convalescent plasma Oxygen therapy Desaturation Medicine R Biology (General) QH301-705.5 Science (General) Q1-390 Karin Holm Maria N. Lundgren Jens Kjeldsen-Kragh Oskar Ljungquist Blenda Böttiger Christian Wikén Jonas Öberg Nils Fernström Ebba Rosendal Anna K. Överby Julia Wigren Byström Mattias Forsell Mona Landin-Olsson Magnus Rasmussen Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
description	Abstract Objective Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19. Results Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6–15) for the convalescent plasma group and 7 days (IQR 5–9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08–2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.
format	article
author	Karin Holm Maria N. Lundgren Jens Kjeldsen-Kragh Oskar Ljungquist Blenda Böttiger Christian Wikén Jonas Öberg Nils Fernström Ebba Rosendal Anna K. Överby Julia Wigren Byström Mattias Forsell Mona Landin-Olsson Magnus Rasmussen
author_facet	Karin Holm Maria N. Lundgren Jens Kjeldsen-Kragh Oskar Ljungquist Blenda Böttiger Christian Wikén Jonas Öberg Nils Fernström Ebba Rosendal Anna K. Överby Julia Wigren Byström Mattias Forsell Mona Landin-Olsson Magnus Rasmussen
author_sort	Karin Holm
title	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
title_short	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
title_full	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
title_fullStr	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
title_full_unstemmed	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
title_sort	convalescence plasma treatment of covid-19: results from a prematurely terminated randomized controlled open-label study in southern sweden
publisher	BMC
publishDate	2021
url	https://doaj.org/article/b7713b8a6ec64937b394d31d9f097f2f
work_keys_str_mv	AT karinholm convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT marianlundgren convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT jenskjeldsenkragh convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT oskarljungquist convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT blendabottiger convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT christianwiken convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT jonasoberg convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT nilsfernstrom convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT ebbarosendal convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT annakoverby convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT juliawigrenbystrom convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT mattiasforsell convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT monalandinolsson convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden AT magnusrasmussen convalescenceplasmatreatmentofcovid19resultsfromaprematurelyterminatedrandomizedcontrolledopenlabelstudyinsouthernsweden
_version_	1718372097785331712

Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Ejemplares similares